دورية أكاديمية
Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic Transplant.
| العنوان: | Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic Transplant. |
|---|---|
| المؤلفون: | Fanelli F; Haematology Unit and Stem Cell Transplant, AO San Camillo Roma, Rome, Italy., Hohaus S; Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore Roma, Rome, Italy.; Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS Roma, Rome, Italy., Cantonetti M; Dipartimento di Oncoematologia Fondazione Policlinico Tor Vergata Roma, Rome, Italy., Cimino G; UOC Ematologia e Centro Trapianto Ospedale Santa Maria Goretti Latina, Latina, Italy., Pennese E; UOC Ematologia Clinica Ospedale Civile Pescara, Pescara, Italy., Battistini R; Haematology Unit and Stem Cell Transplant, AO San Camillo Roma, Rome, Italy., Galli E; Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS Roma, Rome, Italy., Cerretti R; Dipartimento di Oncoematologia Fondazione Policlinico Tor Vergata Roma, Rome, Italy., Proia A; Haematology Unit and Stem Cell Transplant, AO San Camillo Roma, Rome, Italy., Fatone F; Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS Roma, Rome, Italy., Provenzano I; Dipartimento di Oncoematologia Fondazione Policlinico Tor Vergata Roma, Rome, Italy., Abruzzese E; UOC Ematologia Ospedale Sant'Eugenio Roma, Rome, Italy., Finolezzi E; UOC Ematologia AO San Giovanni Addolorata Roma, Rome, Italy., Pulsoni A; Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Rome, Italy., Rigacci L; Department of Medicine and Surgery, Università Campus Bio-Medico Roma, Rome, Italy. |
| المصدر: | Chemotherapy [Chemotherapy] 2023; Vol. 68 (3), pp. 131-137. Date of Electronic Publication: 2022 Dec 22. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Karger Country of Publication: Switzerland NLM ID: 0144731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9794 (Electronic) Linking ISSN: 00093157 NLM ISO Abbreviation: Chemotherapy Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, New York, Karger. |
| مواضيع طبية MeSH: | Hodgkin Disease*/drug therapy , Hematopoietic Stem Cell Transplantation*/adverse effects, Humans ; Salvage Therapy/methods ; Retrospective Studies ; Transplantation, Homologous/adverse effects ; Neoplasm Recurrence, Local ; Brentuximab Vedotin/therapeutic use |
| مستخلص: | Background: Allogeneic transplant is an effective salvage therapy in patients with Hodgkin lymphoma (HL) relapsed or refractory (R/R) to previous treatments. In recent years, immunotherapies (conjugated antibody and checkpoint inhibitors [CPI]) showed interesting results and were used as bridge therapies to allotransplant. Aim: The aim of this retrospective study in Lazio region was to evaluate the impact of these new therapies on outcome after allogeneic hematopoietic stem cell transplantation (allo-SCT) in comparison with standard chemotherapies used in the past. Methods: We selected all consecutive patients with diagnosis of HL transplanted in four hematology transplant units, and we collected data obtained from patients' records concerning all the treatments before allo-SCT. Results: A total of 56 patients were enrolled in this study. All patients underwent allo-SCT for R/R HL. Seventeen patients (30%) received chemotherapy prior to allo-SCT (group B); they were treated between 2008 and 2015; and 39 patients (70%) received brentuximab vedotin (BV), CPI, or both before allo-SCT as a bridge to transplant (group A); they were treated between 2012 and 2020. Twenty-five patients were treated with BV alone, 2 with CPI alone, and 12 first with BV and then with CPI. No patient received concomitant BV and CPI. At 5 years from allo-SCT, overall survival (OS) was 59% and progression-free survival (PFS) was 65%. No statistical differences in OS or PFS were observed between patients in groups A and B. Relapse was significantly associated with a lower survival. The only factor associated with a reduced risk of relapse was development of any grade acute graft versus host disease (GVHD) (p > 0.02). Conclusions: This regional real-world experience shows the changes that have taken place in the last 10 years in R/R HL using new drugs to render a patient eligible for allo-SCT. This strategy appears to guarantee an impressive disease control with an increased risk of complications, for example, aGVHD, that appear to nullify this advantage at least in part. (© 2022 S. Karger AG, Basel.) |
| فهرسة مساهمة: | Keywords: Allogeneic transplant; Hodgkin lymphoma; Refractory disease; Relapsed lymphoma; Salvage therapy |
| المشرفين على المادة: | 7XL5ISS668 (Brentuximab Vedotin) |
| تواريخ الأحداث: | Date Created: 20221222 Date Completed: 20230914 Latest Revision: 20230914 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1159/000525819 |
| PMID: | 36549287 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1421-9794 |
|---|---|
| DOI: | 10.1159/000525819 |